Related references
Note: Only part of the references are listed.Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review
Laurence Leber et al.
PULMONARY CIRCULATION (2021)
Review Current and emerging therapeutic approaches to pulmonary hypertension
Malik Bisserier et al.
REVIEWS IN CARDIOVASCULAR MEDICINE (2020)
Predicting Survival in Patients With Pulmonary Arterial Hypertension The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies
Raymond L. Benza et al.
CHEST (2019)
Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline and Expert Panel Report
James R. Klinger et al.
CHEST (2019)
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
Marc Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Gerald Simonneau et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
J. Gerry Coghlan et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2018)
Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study
Kazuko Mihara et al.
PLOS ONE (2018)
General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018
Ekkehard Gruenig et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients
R.L. Benza et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2017)
Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
Olivier Sitbon et al.
EUROPEAN RESPIRATORY REVIEW (2017)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2016)
Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension A Network Meta-Analysis
Huijun Zhang et al.
MEDICINE (2016)
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
Olivier Sitbon et al.
AMERICAN HEART JOURNAL (2014)
Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
Yuichi Tamura et al.
ADVANCES IN THERAPY (2013)
Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
Andrei Seferian et al.
EUROPEAN RESPIRATORY REVIEW (2013)
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
Olivier Lambert et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
Pathways in pulmonary arterial hypertension: the future is here
Olivier Sitbon et al.
EUROPEAN RESPIRATORY REVIEW (2012)
The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States How REVEAL Differs From Historic and Non-US Contemporary Registries
Adaani E. Frost et al.
CHEST (2011)
How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
R. Barst
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
D. Montani et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation
Y-F Chen et al.
HEALTH TECHNOLOGY ASSESSMENT (2009)
Pulmonary hypertension: Past, present and future
Robyn J. Barst
ANNALS OF THORACIC MEDICINE (2008)
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
M. Gomberg-Maitland et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Combination of bosentan with epoprostenol in pulmonary arterial hypertension:: BREATHE-2
M Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Mechanisms of disease: Pulmonary arterial hypertension
HW Farber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Physiologic basis for the treatment of pulmonary hypertension
H Olschewski et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2001)
Share Paper
